The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) glycopyrrolate and indacaterol maleate; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative, (e) a pharmacologically acceptable stabilizer.

An electronic vaping device is provided including a power supply portion comprising a power supply, an atomizer/liquid reservoir portion comprising a liquid reservoir storing a liquid, and an atomizer adapted to atomize the liquid stored in the liquid reservoir when operated by the power supply. The atomizer is adapted to float on the surface of the liquid in the liquid reservoir.

An aerosol delivery or electronic nicotine delivery systems (“ENDS”) device may include smoking articles that produce aerosol. The device may operate upon authentication. The authentication may first include an age verification before an authentication allows for operation of the device. The authentication may include a control signal communication to the device. The control signal communication may include an audio signal, such as an authentication tone that is detected by a microphone or pressure sensor on the device. The control signal communication may include a visual, optical, or light signal that is detected by a light sensor or photodiode on the device.

A portable inhalation device includes a medication storage component, a flow controller, an atomizer, a medication delivery component, and a pressure sensor. The medication storage component is configured to store medication. The flow controller is configured to cause a force to be applied to the medication stored by the medication storage component to transport the medication to the atomizer. The atomizer is configured to generate droplets from the medication. The medication delivery component includes a delivery channel extending from the atomizer to an outlet opening. The medication delivery component is configured to receive the medication in the delivery channel from the atomizer and dispense the medication via the opening. The pressure sensor is configured to detect a pressure corresponding to a flow rate of air in the delivery channel and output an indication of the detected pressure.

An information processing method according to an embodiment of the present invention comprises: a step for receiving usage status information representing the usage status of an aerosol generation device for generating aerosol; a step for giving a reward to the user of the aerosol generation device on the basis of the received usage status information; and a step for notifying a terminal device of information relating to the reward, said terminal device being capable of communicatively connecting with the aerosol generation device.

The present invention provides for the integration of drug dispersion methods into a drug or medicine delivery system. The drug dispersion methods used include shear (e.g., air across a drug, with or without a gas assist), capillary flow or a venturi effect, mechanical means such as spinning, vibration, or impaction, and turbulence (e.g., using mesh screens, or restrictions in the air path). These methods of drug dispersion allow for all of the drug in the system to be released, allowing control of the dosage size. These methods also provide for drug metering, fluidization, entrainment, deaggragation and deagglomeration. The present invention also provides for the integration of a drug sealing system into the device. The drug sealing system provides a way of blocking the migration of drug from one area of the package to another. The drug seal system can also provide a method of tightly containing the drug until the package is opened, of directing airflow through the package and of managing and containing the drug during the package/device manufacturing process.

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

An aerosol generator (1) with an active liquid container (4) and a nebulization chamber (2) associated therewith, which is connected to an inlet channel (10) for the supply of carrier gas and to an outlet channel (12) for the discharge of carrier gas mixed with aerosol obtained from the active liquid, is intended to enable a particularly good adjustability of the droplet size of the aerosols contained in the discharged carrier gas and thus a use particularly in the context of a transnasal inhalation therapy. For this purpose, the nebulization chamber (2) has a substantially rotationally symmetrical boundary wall (8), the inlet channel (10) being positioned and oriented in the region of its point of entry into the nebulization chamber (2) in such a way that its longitudinal axis is offset relative to the axis of symmetry of the nebulization chamber (2) in the region of the point of entry and does not intersect the axis of symmetry.

Provided is a nasal drop device which can simply and easily administer an appropriate amount of a solution to a specific site in the nasal cavity without waste. The nasal drop device 100 includes: an ejection portion 104 that ejects droplets into the nasal cavity; and a control portion that acquires suitability information indicating whether or not a current relative angle between a reference line indicating the posture of the face of a user who puts the nasal drop device 100 in the nose and a reference line indicating the posture of the nasal drop device 100 is suitable for the nasal drop, and controls the ejection operation of the ejection portion 104 according to the suitability information.

A method for performing an inhalation using a nebulizer includes filling a reservoir with a medication fluid or connecting a medication container to a designated connecting piece: connecting a nebulizer unit to a control unit and a mouthpiece, at least temporarily activating the nebulizer unit; atomizing the medication fluid into a fine particulate aerosol which is emitted into an aerosol chamber formed by the nebulizer unit and the mouthpiece during activation of the nebulizer unit; performing the inhalation, with a user enclosing the mouthpiece with the lips and during inhalation, drawing air from outside into the aerosol chamber, where the air mixes with the aerosol, and then passes further through the mouthpiece as an air stream and into the respiratory tract and, possibly into the user's lung; measuring a pressure within the aerosol chamber and/or a flow rate through the aerosol chamber or the mouthpiece using the control unit; activating the nebulizer unit with each breath on occurrence of at least one activation criterion detected using the control unit; and deactivating the nebulizer unit with fulfilment of at least one stop criterion, wherein from a degree of fulfilment of the at least one activation and/or stop criterion, a weighted average value is formed and the inhalation is started when the weighted average value exceeds a threshold value.